A set of glycoproteins recognized by A2B5 antibody with major bands at 55 and 76 kDa is overexpressed in human head and neck squamous cell carcinomas

Bolot, G.; Popa, Iuliana; Paret, Marie Julie; David, M.; Schmitt, Daniel; Portoukalian, Jacques

doi:10.1016/s0300-9084(03)00044-0

Cited by 2 publications

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The expression of NG2 is also reported in other cell types such as endothelial cell and smooth muscle cell progenitors (24); therefore, we next validated these data by immunoblotting of spinal cord tissue homogenates with anti‐A2B5 and anti‐PDGF‐αR antibodies, which cross‐react with gangliosides (25) or glycoprotein (26), and PDGF‐αR (27) proteins, respectively, expressed in dividing OPs. There was a relative decrease in both A2B5 glycoprotein (a major cross reacting band of 70 kDa was observed in addition to several minor bands of greater than 120 kDa and from 30 to 40 kDa) and PDGF‐αR (150 kDa) proteins in EAE animals compared with LOV‐treated EAE animals and controls (Fig.…”

Section: Resultsmentioning

confidence: 58%

HMG‐CoA reductase inhibitor augments survival and differentiation of oligodendrocyte progenitors in animal model of multiple sclerosis

et al. 2005

View full text Add to dashboard Cite

Impaired remyelination due to degeneration of both postmitotic oligodendrocytes and oligodendrocyte progenitors (OPs) is the major hallmark of inflammatory demyelination in multiple sclerosis (MS) lesions and experimental autoimmune encephalomyelitis (EAE). Here, we have demonstrated the potential of lovastatin, a HMG-CoA reductase inhibitor, for the restoration of impaired remyelination mediated through enhanced survival and differentiation of OPs in the spinal cord of treated EAE animals. Lovastatin treatment significantly increased the level of myelin lipids in the spinal cord of treated EAE animals, coinciding with the attenuation of disease severity and inflammatory demyelination as compared with untreated EAE animals. The increased expression of myelin proteins and transcription factors associated with differentiating oligodendrocytes along with the increase in number of NG2+/BrdU- and NG2+/BrdU+ cells, and the expression of proliferating OP-specific proteins, demonstrated the restoration of remyelination in the spinal cord of lovastatin-treated EAE animals. Corresponding to this, in vitro studies further corroborated the increased survival and differentiation of OPs in lovastatin-treated activated mixed glial cells suggesting that lovastatin protects against the degeneration of OPs and enhances their differentiation through induction of a pro-remyelinating environment in the spinal cord of treated EAE animals. Together, these data demonstrate that lovastatin has the potential to augment remyelination in MS lesions and other neuroinflammatory diseases.

show abstract

Section: Resultsmentioning

confidence: 58%

HMG‐CoA reductase inhibitor augments survival and differentiation of oligodendrocyte progenitors in animal model of multiple sclerosis

et al. 2005

View full text Add to dashboard Cite

show abstract

Targeting Glioblastoma Stem Cells: Cell Surface Markers

He¹,

Liu²,

Lubman³

2012

Current Medicinal Chemistry

View full text Add to dashboard Cite

Glioblastoma multiforme (GBM) is the most common primary brain tumor and among the most lethal cancers. There is increasing evidence that cancer stem cells within GBMs, which are often referred to as glioblastoma stem cells (GSCs), play a critical role in tumor initiation and maintenance. Identification of novel markers for GSCs will lead to better targeting of GSCs which could have tremendous impact on treatment of GBMs. Cell surface markers are particularly suitable as therapeutic targets. Although several promising cell surface markers have successfully been used for enrichment of GSCs, their functional roles in maintenance of GSC properties as well as in GBM formation and development remain to be characterized. In this review, we primarily summarize recent advances in identification of GSC markers, with a particular focus on cell surface markers.

show abstract

A set of glycoproteins recognized by A2B5 antibody with major bands at 55 and 76 kDa is overexpressed in human head and neck squamous cell carcinomas

Cited by 2 publications

References 12 publications

HMG‐CoA reductase inhibitor augments survival and differentiation of oligodendrocyte progenitors in animal model of multiple sclerosis

HMG‐CoA reductase inhibitor augments survival and differentiation of oligodendrocyte progenitors in animal model of multiple sclerosis

Targeting Glioblastoma Stem Cells: Cell Surface Markers

Contact Info

Product

Resources

About